Shaun Furlong has been appointed as an Executive Director of Allergy Therapeutics plc, an integrated commercial biotechnology firm that specializes in allergy vaccinations. The appointment will take effect on March 8, 2024.
After serving as the Group Financial Controller since April 2022, Shaun was named the Group’s Chief Financial Officer (CFO) in August 2023. Having held top finance positions in various blue-chip organizations, such as Legal & General, Hastings Direct, Volution Group, and American Express, he brings a wealth of financial knowledge to the table. Shaun received his PhD in polymer chemistry from the University of Sussex and is a Fellow of the Institute of Chartered Accountants in England and Wales.
Shaun has shown himself to be a tremendous addition to the company since being appointed Group Financial Controller and, more recently, Chief Financial Officer last year, according to Allergy Therapeutics Chairman Peter Jensen. He has a wealth of expertise, excellent financial sense, and professionalism, so he will undoubtedly be a valuable addition to the Board.
Shaun Furlong made the following statement regarding his appointment It gives me great pleasure to assume a more expansive leadership role as an Executive Director, and he look forward to working with the other members of the Board.
